Abstract Captopril (SQ 14 225) was administered to normotensive, sodium-replete
volunteers in order to investigate the relationships between its haemodynamic effects and …

In a double-blind randomized study, the dose response to captopril was studied in 12
severely hypertensive patients whose blood pressure had been previously controlled by this …

To compare the hemodynamic and humoral effects of increasing doses of captopril, blood
pressure, heart rate, plasma renin activity, plasma aldosterone and angiotensin-converting …

Dose‐response curves of blood pressure and of the biochemical components of the renin‐
angiotensin‐aldosterone system were determined during long‐term treatment with captopril …

To evaluate the role of regional hemodynamics in mediating the long-term depressor effect
of the converting enzyme inhibitor, captopril, at a low dose (37.5 mg/day), for 2 weeks, its …

Captopril was given alone and in combination with diuretics to 49 patients with hypertension
for 1 to 12 mo. Within 2 mo blood pressure reduction correlated with pretreatment plasma …

The effects of captopril on blood pressure and plasma angiotensin-converting enzyme were
studied in cats with two-kidney, one-clip experimental hypertension. The time period for the …

Captopril inhibits angiotensin II formation and bradykinin degradation in vivo. Eleven
patients with essential hypertension (EH) and four patients with renovascular hypertension …

Captopril (SQ 14 225), an orally active inhibitor of angiotensin converting enzyme, was
evaluated in the treatment of primary (essential) hypertension in a placebo‐controlled long …

Captopril was given to 15 unselected patients with essential hypertension (WHO II) at a dose
range of 300 to 600 mg/day. Hemodynamic indexes (thermodilution) as well as levels of …